North America COPD & Asthma Devices Market
[ClickPress, Fri Nov 18 2016] According to a recently published report by KBV Research, the North America COPD & Asthma Device Market attained a market size of $7,039.1 Million in 2015 and is expected to reach $8,786.6 Million by 2022 growing at a CAGR of 3.3% CAGR during 2016 - 2022.
The US market dominated the North America COPD & Asthma Device Market in 2015 and would continue till 2022, growing at a CAGR of 2.5% during the forecast period. The Canada market is expected to reach a market size of $1,318.0 Million by 2022. The Mexico market would witness the high growth rate of 7.6% during 2016-2022.
The Pneumatic Nebulizers market dominated the North America COPD & Asthma Nebulizer Market in 2015 and would continue till 2022 thereby achieving a market value of $942.8 Million by 2022 growing at a CAGR of 3.2% during the forecast period. The Mesh Nebulizer market would witness the high growth rate of 3.2% during 2016-2022.
The report highlights the adoption of COPD & Asthma Devices in North America. Based on the product type; the market is segmented into Inhalers and Nebulizers market. Further the Inhaler segment is sub segmented into Dry Powder Inhalers, Metered Dose Inhalers and Soft Mist Inhalers Market. The Nebulizers segment is bifurcated into Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers Market. The countries included in the report are U.S, Canada, Mexico and Rest of North America.
Key players profiled in the report include Glaxosmithcline PLC., Novartis International AG., Biotronik SE & Co. KG., AstraZeneca Plc., 3M Healthcare, GF Health Products, Inc., Sunovion Pharmaceuticals Inc., Smith Medicals, Inc., Baxter International and Philips.